Four Decades for Justice
Cravath represented the underwriters, led by BofA Merrill Lynch, Goldman, Sachs & Co., J.P. Morgan Securities, Citigroup, Deutsche Bank Securities and RBS, in connection with the US$3.5 billion registered debt offering of Johnson & Johnson, a company engaged in the manufacturing and sale of a broad range of products in the healthcare field. The transaction closed on December 5, 2013.
The Cravath team included partner Craig F. Arcella and associates Andy Ham and Thomas K. Wiesner II. Cameron S. Stanton also worked on this matter.
Deals & Cases
November 01, 2022
On November 1, 2022, Johnson & Johnson and Abiomed, a leader in breakthrough heart, lung and kidney support technologies, announced that they have entered into a definitive agreement under which Johnson & Johnson will acquire through a tender offer all outstanding shares of Abiomed, for an upfront payment of $380 per share in cash, corresponding to an enterprise value of approximately $16.6 billion which includes cash acquired. Abiomed shareholders will also receive a non-tradeable contingent value right (“CVR”) entitling the holder to receive up to $35 per share in cash if certain commercial and clinical milestones are achieved. Cravath is representing Johnson & Johnson in connection with the transaction.
Celebrating 200 years of partnership. In 2019, we celebrated our bicentennial. Our history mirrors that of our nation. Integral to our story is our culture.
Attorney Advertising. ©2024 Cravath, Swaine & Moore LLP.